Strontium
Research reviewed: Up until 03/2026
Strontium (Strontium (as Strontium Ranelate or Strontium Citrate)) is a dietary supplement with 5 published peer-reviewed studies involving 12,000 participants, researched for Bone Health & Fracture Prevention.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Bone Health & Fracture Prevention
StrongResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Bone Health & Fracture Prevention
To assess strontium ranelate efficacy for vertebral fracture risk reduction in postmenopausal osteoporosis.
Study Type
Randomised, double-blind, placebo-controlled Phase III trial (SOTI)
Purpose
To assess strontium ranelate efficacy for vertebral fracture risk reduction in postmenopausal osteoporosis.
Dose
Strontium ranelate 2g daily
Participants
1649 postmenopausal women with osteoporosis
Duration
3 years
Results
41% reduction in relative risk of vertebral fracture (p<0.001). BMD increased 14.4% at lumbar spine. Absolute risk reduction clinically significant. Well tolerated.
How They Measured It
Vertebral fracture incidence (X-ray), BMD at lumbar spine and femoral neck
To assess strontium ranelate for non-vertebral and hip fracture reduction.
Study Type
Randomised, double-blind, placebo-controlled Phase III trial (TROPOS)
Purpose
To assess strontium ranelate for non-vertebral and hip fracture reduction.
Dose
Strontium ranelate 2g daily
Participants
5091 postmenopausal women with osteoporosis
Duration
5 years
Results
36% reduction in vertebral fracture risk maintained at 5 years. 16% reduction in non-vertebral fractures. Hip fracture risk reduced 36% in high-risk subgroup (age 74+). Durable long-term effect.
How They Measured It
Non-vertebral fracture incidence, hip fracture rate, BMD at femoral neck
To evaluate strontium ranelate for preventing and treating postmenopausal osteoporosis.
Study Type
Cochrane systematic review
Purpose
To evaluate strontium ranelate for preventing and treating postmenopausal osteoporosis.
Dose
Strontium ranelate 2g daily
Participants
6981 participants (multiple RCTs)
Duration
3-5 years
Results
Significant reduction in vertebral and non-vertebral fracture risk confirmed. Unique dual bone action (formation stimulation + resorption inhibition) demonstrated. Generally well tolerated.
How They Measured It
Fracture rates, BMD, adverse events across all major RCTs
To review strontium ranelate management of osteoporosis and dual mechanism of action.
Study Type
Review - mechanistic
Purpose
To review strontium ranelate management of osteoporosis and dual mechanism of action.
Dose
Strontium ranelate 2g daily
Participants
Review of major Phase III RCTs
Duration
N/A
Results
Strontium ranelate uniquely stimulates bone formation AND inhibits bone resorption simultaneously. This dual action distinguishes it from bisphosphonates (resorption only) and anabolics (formation only).
How They Measured It
Review of 4 major Phase III RCTs and preclinical mechanistic studies
To assess strontium citrate supplement effects on bone turnover markers in postmenopausal women.
Study Type
Clinical trial
Purpose
To assess strontium citrate supplement effects on bone turnover markers in postmenopausal women.
Dose
Strontium citrate providing 340mg elemental strontium daily
Participants
60 postmenopausal women
Duration
12 months
Results
Strontium citrate significantly improved bone turnover markers. Osteocalcin increased (bone formation) while CTX decreased (bone resorption). BMD improvement at lumbar spine.
How They Measured It
Bone formation (osteocalcin, PINP) and resorption markers (CTX), BMD
Frequently Asked Questions
Common questions about Strontium research
There are currently 68 peer-reviewed studies on Strontium (Strontium (as Strontium Ranelate or Strontium Citrate)), involving 12,000 total participants. Research covers Bone density, Fracture prevention, Osteoporosis treatment and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (5 human studies), and reported outcomes.
Strontium has been researched for: Bone density, Fracture prevention, Osteoporosis treatment, Bone formation stimulation. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 5 out of 68 studies are human trials. Human trials carry more weight in our evidence scoring system.
